OR WAIT null SECS
Rita C. Peters is editorial director of BioPharm International, Pharmaceutical Technology, and Pharmaceutical Technology Europe.
A different perspective on controlling fixed costs of biomanufacturing, based on know-how from other industries, provides a competitive edge, says the CEO of Samsung BioLogics.
Digital technologies and information sciences have helped advanced medical science and research, a lesson that was obvious to Dr. Tae Han Kim, CEO and president of Samsung BioLogics, when he was researching new business areas for Samsung about 10 years ago. His recommendation-to enter the biologics drug contract manufacturing market, an area in which it had no prior experience-leveraged the company’s manufacturing and plant construction expertise and has provided the company a competitive edge, he says, in the contract manufacturing market.
Read this article in BioPharm International'sOutsourcing Resources 2018 eBook.
View other articles in BioPharm International's Outsourcing Resources 2018 eBook.
eBook: Outsourcing Resources 2018
When referring to this article, please cite it as R. Peters, “Bigger is Better in Samsung’s Approach to Biomanufacturing," BioPharm International Outsourcing Resources eBook (March 2018).